SB
Syntax Bio
United States · Biotech · Healthtech
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A+ | $14.4M | Allegis Capital — Role not disclosedAstellas Venture Management — Role not disclosedCivilization Ventures — Role not disclosedDCVC Bio — Role not disclosedDraper Associates — Role not disclosedEGB Capital — Role not disclosedExit Fund — Role not disclosedIllinois Ventures — Role not disclosedIllumina Ventures — Role not disclosedLongGame — Role not disclosedMansueto Office — Role not disclosedMayo Clinic — Role not disclosedPortal Innovations — Role not disclosedSigma Group — Role not disclosedthe Illinois Department of Commerce and Economic Opportunity — Role not disclosedWalder Ventures — Role not disclosed |